Location History:
- Brussels, BE (2002 - 2003)
- Paris, FR (2004)
- Saint-Denis cedex, FR (2008)
Company Filing History:
2 out of 525 
2 out of 832,912 Years Active: 2002-2008
Title: Marie-Therese Duffour: Innovator in Cancer Research
Introduction
Marie-Therese Duffour is a prominent inventor based in Brussels, Belgium. She has made significant contributions to the field of cancer research, particularly in the isolation of cytotoxic T lymphocyte (CTL) clones. With a total of 4 patents to her name, her work has the potential to impact the diagnosis and treatment of various pathological conditions.
Latest Patents
One of her latest patents focuses on tumor antigens and CTL clones isolated by a novel procedure. This invention relates to the isolation of CTL clones that are specific for proteins of the MAGE family. The CTL clones have been isolated through successive steps of stimulation and testing of lymphocytes with antigen-presenting cells that present antigens derived from different expression systems. Additionally, she has developed nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of these nucleic acid molecules is one that codes for the peptide GVYDGREHTV, which binds to HLA-A2. These innovations are crucial for advancing cancer diagnostics and therapies.
Career Highlights
Throughout her career, Marie-Therese Duffour has worked with esteemed organizations, including the Ludwig Institute for Cancer Research Limited. Her research has been instrumental in furthering our understanding of immune responses to cancer.
Collaborations
Marie-Therese has collaborated with notable colleagues such as Rosalie Luiten and Nathalie Demotte, contributing to a rich exchange of ideas and advancements in cancer research.
Conclusion
Marie-Therese Duffour's innovative work in the field of cancer research exemplifies the impact of dedicated inventors on medical science. Her patents and collaborations continue to pave the way for new therapeutic approaches in oncology.